Introduction
Adenovirus-based gene therapy has been proposed as a novel drug-delivery system for the targeted administration of protein-based therapies, including growth factors and biological response modifier. [1] [2] [3] However, inflammation and the immune response associated with adenovirus-mediated gene transfer have raised concerns about the safety and efficacy of its use in acute inflammatory diseases. 4, 5 In particular, concern has been raised about the systemic administration of first-generation adenoviral recombinants in sepsis and endotoxicosis. For example, Doerschug et al. 6 reported that the systemic administration of first-generation adenoviral recombinants actually increased mortality in a model of generalized polymicrobial sepsis. We have also reported that intravenous administration of adenovirus exacerbates apoptotic liver injury to a subsequent challenge with D-galactosamine and lipopolysaccharide. 7 In contrast to systemic administration, local delivery of adenovirus has been well tolerated. In fact, adenovirus recombinants are currently in clinical trials as a means to ectopically express growth factors and cytokines for targeted treatment of cancer, rheumatoid arthritis, and chronic wounds. [8] [9] [10] We have reported that intratracheal instillation of an E1,E3-deleted adenovirus expressing interleukin-10 (IL-10) can generate local production of IL-10 11, 12 and can modify outcome in a number of chronic and acute inflammatory processes, including sepsis and acute pancreatitis. 13 Similar results were not seen when the same recombinants were given systemically. In a previous study, we demonstrated improved outcome and reduced lung injury in response to adenoviral expression of IL-10 in a zymosan-induced model of acute lung injury and multisystem organ failure (MSOF). 13 Standiford et al. 14, 15 have reported similar results using adenovirus with other biological response modifiers in additional models of acute lung injury.
In this report, we utilized a murine model of acute lung injury and MSOF, induced by the intraperitoneal (i.p.) administration of zymosan. First described by Goris, 16 the zymosan model is triphasic, characterized by an early shock period in which mortality is approximately 15-25% in the first 72 h. The surviving animals then stabilize for a period of about 7-10 days, after which mortality increases dramatically as the animals succumb to acute respiratory failure and MSOF.
The zymosan model is novel because organ injury develops over a relatively long period, 14-21 days, as compared to other murine models of inflammation, such as endotoxicosis, delivery of live bacteria, or cecal ligation and puncture models, where organ injury is maximal in hours to a few days. Other models of lung injury that develop on a more chronic time-scale include bleomycin-and radiation-induced fibrosis. Parenteral administration of bleomycin, a chemotherapeutic agent, leads to increased permeability of the alveolar-capillary barrier, inflammatory cell influx and fibroblast hyperplasia, which leads to deposition of extracellular matrix and loss of elasticity with scar tissue formation. 17 This results in impaired gas exchange, and pulmonary fibrosis. Similarly, ionizing radiation to the thorax causes three overlapping phases of lung injury, the latent period, the pneumonic phase, and the fibrotic phase. Development of both inflammatory and fibrotic injury is mediated by resident pulmonary macrophages as well as newly recruited cells, which express growth factors that can exacerbate fibrosis. Peak development of inflammation in this chronic model occurs at 4 weeks. However, both bleomycin-and radiation-induced methods of chronic lung injury do not create the picture of multisystem organ failure seen after zymosan administration.
IL-10 is a cytokine expressed in patients and animals with sepsis syndromes. It is produced by T H 2 lymphocytes, monocytes, and epithelial cells and functions to inhibit antigen presenting cells and suppress synthesis of pro-inflammatory cytokines. 18 Understanding the biologic contribution of its simultaneous anti-inflammatory and immunosuppressive properties has made the study of IL-10 challenging. For example, conflicting results have been obtained after systemic administration of anti-IL-10 antibodies. After induction of cecal ligation and puncture, treatment with such antibodies was reported to worsen outcome 19, 20 but interestingly, survival was improved if the cecal ligation and puncture was followed by intratracheal instillation of Pseudomonas 21 or preceded by scald burn. 22 In the present report, we examined whether the dose of adenovirus expressing human or viral IL-10 delivered intratracheally contributed to outcome in a zymosan model of acute lung injury and MSOF. Intratracheal delivery of low levels of recombinant adenoviral vectors expressing IL-10 was associated with localized expression of IL-10 and improved outcome. However, when the doses of adenovirus were increased to a level where systemic appearance of IL-10 was observed, outcome was dramatically reduced, and there was evidence of increased systemic inflammation. These findings suggest that adenovirus-directed, compartmentalized expression of IL-10 can be used to target localized inflammation, but increasing doses that result in the systemic appearance of IL-10 are not associated with improvements in outcome or reductions in the inflammatory response.
Results and discussion
In a previous report, 13 we observed that targeted lung expression of viral or human IL-10 delivered by a firstgeneration adenoviral recombinant could reduce lung injury and inflammation, and improve outcome in a zymosan model of acute lung injury and MSOF. In that report, we demonstrated that intra-tracheal pretreatment with the adenovirus expressing IL-10 was required, whereas intravenous administration of equivalent quantities of adenovirus was ineffective. Lung expression of viral IL-10 was more effective than human IL-10, and this appeared to be due to prolonged compartmentalized expression of viral IL-10 (versus human IL-10) in the lungs of these infected mice. These results confirmed our earlier findings in healthy mice that adenoviral expression of viral IL-10 was associated with prolonged and more specific local expression compared to human IL-10. 11, 12 In the present report, we confirmed that at a dose of particles of recombinant adenoviral vectors. This study was terminated on day 8 because all of the mice treated with 10 9 p of Ad/hIL-10 had expired, and survival was worse in the Ad/vIL-10-treated group than in the buffer-treated group.
IL-10 gene therapy in MSOF PF McAuliffe et al produced significant improvements in outcome ( Figure  1a , survival after induction of zymosan lung injury with pre-treatment with buffer or various adenoviral vectors at 10 7 particles). As seen previously, 13 the effects of adenoviral recombinants expressing viral IL-10 were markedly better than those seen with human IL-10, although both treatments improved outcome significantly. In animals pretreated with adenovirus expressing viral IL-10, mortality 18 days after zymosan administration was less than 10%, whereas mortality was 50% for animals pretreated with adenovirus expressing human IL-10, and 100% for the vehicle-treated animals. Interestingly, the instillation of an empty adenovirus recombinant also improved outcome to some extent.
We then asked if outcome could be further improved by increasing the dose of adenoviral recombinants administered intratracheally to 10 8 and 10 9 viral particles for different recombinants. At the intermediate adenoviral dose (10 8 particles), the improvement in outcome seen with human and viral IL-10 expression, when compared to the empty recombinant, was lost ( Figure 1b , survival after induction of zymosan lung injury with pretreatment with buffer or various adenoviral vectors at 10 8 particles). All three treatments prolonged survival modestly compared to the buffer treated group, but the expression of the human IL-10 was associated with a trend toward an adverse outcome when compared to the viral IL-10 or Ad/empty groups.
At the highest dose (10 9 particles), however, the study was terminated on day 7 because outcome in the animals treated with this dose of recombinant adenovirus expressing human or viral IL-10 was dramatically worse than either the vehicle or Ad/empty-treated animals ( Figure 1c , survival after induction of zymosan lung injury with pretreatment with buffer or various adenoviral vectors at 10 9 particles). By day 7, all of the mice expressing human IL-10 had expired.
The question that naturally arises from these results is, what can explain this very dramatic difference in outcome based on the dose of adenovirus administered. One potential explanation could be the adverse effects of increasing adenoviral load in the treated groups. We and others have shown that the intratracheal instillation of adenovirus induces a local inflammatory response characterized by production of TNF-a. 11 Interruption of TNF signaling has been shown to attenuate the innate and acquired immune responses to the adenovirus recombinants directly. 23, 24 One explanation may be that the increased adenovirus load heightened the inflammatory response to the zymosan administration, and exacerbated the lung injury.
Most problematic with this explanation is the observation that administration of increasing doses of the empty Ad vectors did not lead to progressively worse outcomes in this model (Figure 1 , survival after induction of zymosan lung injury with pretreatment with buffer or various adenoviral vectors). Rather, outcome in the Ad/ empty group remained better than the vehicle control at all of the doses examined. Furthermore, we could not see a significant difference in the inflammatory cytokine response in the plasma or lungs of mice with increasing quantities of empty adenovirus recombinants (data not shown).
Instead, the loss of beneficial effect with localized expression of IL-10 appeared to be dependent on the tissue concentrations and the systemic appearance of IL-10. As shown in Figure 2b (IL-10 concentrations in lung homogenates), levels of human and viral IL-10 in lung homogenates were dependent on the dose of adenovirus administered. At the lowest doses (10 7 particles), IL-10 concentrations expressed in the tissue homogenates were approximately 100-300 pg/g wet weight, but these concentrations increased dramatically as adenoviral dose increased. At the highest doses (10 9 particles), tissue levels exceeded 10-70 000 pg/g wet weight. There were also dose-dependent differences observed in serum concentrations of human and viral IL-10 ( Figure 2a , IL-10 concentrations in plasma). At the lowest dose, where adenovirus expressing either human or viral IL-10 was effective in prolonging outcome, no protein was detected in the circulation. At the intermediate dose, human IL-10 was present in the circulation at 100-300 pg/ml, whereas viral IL-10 was still undetectable, despite similar levels in the tissues. We have previously reported this differential appearance between human and viral IL-10 expressed in rodent tissues, where viral IL-10 appears to be more associated with the tissue homogenates, whereas human IL-10 circulates more freely. 12 At the highest dose (10 9 particles), however, both viral and human IL-10 appeared in the circulation at 1000-3000 pg/ml and were associated with an adverse outcome. Previous 
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studies in patients with severe traumatic injury, ischemiareperfusion injury, or sepsis have demonstrated that elevated plasma IL-10 concentration, in the range of 500-1500 pg/ml, is also associated with an adverse outcome. [25] [26] [27] We previously reported that intratracheal instillation of low dose (10 7 p) adenoviral recombinants expressing IL-10 reduced the magnitude of the inflammatory response to zymosan, 13 and similar results were seen here (data not shown). Interestingly, pretreatment with 10 9 particles of human and viral IL-10 was associated with a significant increase in the magnitude of the inflammatory response, as determined by increased plasma concentrations of TNFa and IL-6 ( Figure 3 ). As shown in panels a-c (IL-6 concentrations in plasma, and TNFa concentrations in plasma and lung homogenates) with Ad/empty doses of 10 7 particles, the plasma and lung response to zymosan was biphasic, characterized by elevated plasma IL-6 concentrations in the immediate postzymosan period, followed by a later increase in plasma and lung TNF-a as MSOF progressed. In mice pretreated with 10 9 particles of adenovirus expressing either human or viral IL-10, all had expired by day 7, and at the last sampling interval (day 5), these animals had significantly elevated plasma IL-6 and TNF-a concentrations compared to mice treated with Ad/empty (panel d, IL-6 or TNFa concentrations in plasma), consistent with an exaggerated inflammatory response. Previous studies have demonstrated that treatment with vehicle alone does not cause such marked cytokine production. 13 The findings reported here are consistent with targeted lung expression of IL-10 at physiologic concentrations reducing the local inflammatory response in that compartment, thereby improving outcome. IL-10 has been shown to suppress expression of TNF-a, IL-1b, and chemokines in response to zymosan. 28 Suppression of TNF-a in this model is also protective. 29, 30 At higher doses, increased IL-10 concentrations were not associated with suppression of the pro-inflammatory response. Often, paradoxical pro-inflammatory responses have been seen with IL-10 administration, which appears to be dependent, in part, on increases in systemic IL-10 levels and on the relative activation state of myeloid cell populations. For example, van der Poll demonstrated that when IL-10 was administered to human volunteers after endotoxicosis, IFN-g, IP-10, and MIG concentrations were enhanced. 31 Cavaillon also observed that IL-10 could potentiate the inflammatory response of blood monocytes to LPS, depending upon their activation state induced by adherence. The plasma and lung concentrations of IL-6 and TNF-a were determined on days 1, 5, 10, and 18 in mice pretreated with 10 7 particles Ad/empty prior to zymosan administration. Concentrations were not significantly different from mice receiving 10 8 and 10 9 particles Ad/empty at the same time points (data not shown). (d) Plasma IL-6 and TNF-a concentrations were evaluated on day 5 in mice pretreated with 10 9 particles of Ad/ vIL-10, Ad/hIL-10, or Ad/empty, the last sampling period before all of the Ad/IL-10 animals expired. Data were analyzed by one-way ANOVA, and post hoc comparisons were performed by Dunn's multiple range test. Both IL-6 and TNF-a concentrations were significantly lower in mice pretreated with Ad/empty than with either Ad/vIL-10 or Ad/hIL-10 (Po0.05).
At higher doses of adenovirus, the plasma IL-10 concentration was elevated to levels reported in sepsissyndromes and trauma that are frequently associated with an adverse outcome. [25] [26] [27] Systemic appearance of IL-10 is thought to contribute to the suppression of myeloidderived cells of the immune system seen following traumatic injury. Consistent with an association between poor outcome and increased serum IL-10 concentration, Mannick and Lederer have shown that blocking endogenous IL-10 attenuates lethality to generalized peritonitis following thermal injury. 22, 33 Under these conditions, over-expression of IL-10 and its systemic appearance are thought to not only suppress macrophage activation, but also lead to suppression of a T h1 lymphocyte response. Furthermore, increased systemic IL-10 is also thought to lead to activation of NK and NKT cell and B-cell populations.
In conclusion, the results from these studies demonstrate that targeted expression of IL-10 can improve outcome in a model of zymosan-induced lung injury and organ failure, but the improvements are adenovirus dose-dependent. Improved survival was associated with a reduction in local and systemic inflammatory response. In contrast, increased adenovirus expression of IL-10 was not associated with improvements in outcome. Although targeted gene expression of IL-10 can be used to modulate the local inflammatory response, increased expression of IL-10 resulting in its systemic release is not associated with improvements in outcome, and may actually exacerbate acute inflammatory processes.
Materials and methods

Zymosan A preparation
Zymosan A (lot no. 49H0557), a cell-wall component of Saccharomyces cerevisiae, and endotoxin-free paraffin oil were obtained from Sigma Fine Chemicals (St Louis, MO, USA). The zymosan A was irradiated with 5 kGy g-radiation over 5 h to destroy any viability of fungal contaminants. Endotoxin content of the zymosan A preparations was less than 500 pg/mg. The irradiated zymosan A was suspended in sterile paraffin oil at a concentration of 0.6 mg/g body weight using sterile technique. The zymosan-paraffin oil suspension was generated by sonicating the preparation in a water bath (50/60 Hz) for 30 min and in a high-frequency sonicator (Fisher Sonic Dismembrator model 300; Fisher Scientific, Pittsburgh, PA, USA) at a setting of 70% for 15 min. The zymosan suspension was then placed in a 1001C water bath for 80 min. After this, the solution was vortexed and drawn into sterile syringes.
Animal preparation
Specific pathogen-free female C57BL/6 mice (20-25 g; The Jackson Laboratory, Bar Harbor, ME, USA) were maintained in a Bio-Safety Level 2 barrier facility with unlimited chow and water for the duration of the experiments. All animal studies were approved by the Institutional Animal Care and Use Committee of the University of Florida prior to initiation. The use of adenoviral recombinants in mice was also approved by the Institutional Biosafety and the Recombinant DNA Committees of the University of Florida. The laboratory adheres to the 'Guiding Principles of Laboratory Animal Care,' as promulgated by the American Physiological Society.
On day À1, mice received an intratracheal instillation of buffer (PBS, pH 7.5, containing 3% (w/v) sucrose, 2 mM MgCl 2 ) or buffer containing a recombinant adenoviral construct, expressing human IL-10 (Ad/hIL-10), viral IL-10 (Ad/vIL-10), or an empty expression cassette (Ad/empty). After induction of anesthesia with i.p. sodium pentobarbital at 35 mg/kg body weight, a midline incision was made in the neck. The trachea was cannulated with a sterile 30-gauge needle, and 32 ml of buffer or adenoviral vector at either 10 7 , 10 8 , or 10 9 particles was delivered. On day 0, all mice received an i.p. injection of 1 ml of the zymosan suspension with a sterile 20-gauge needle. Animals were weighed daily and followed for survival for 18 days (n ¼ 15-24 per group).
Additional mice (n ¼ 9 per group) were killed by cervical dislocation 1, 5, and 10 days after zymosan administration. Blood was collected via retro-orbital venipuncture with a capillary tube. Liver and lungs were removed and snap-frozen in liquid nitrogen.
Analytical methods
Murine IL-6, hIL-10, and vIL-10 levels in the organ homogenates and in the serum were measured by sandwich ELISA with commercially available reagents (mIL-6, hIL-10, and vIL-10 by Endogen, Woburn, MA, USA and murine IL-10 by R&D Systems, Minneapolis, MN, USA). Bioactive TNF-a was measured in serum and lung homogenates with the TNF-a a-sensitive WEHI 164 clone 13 murine fibrosarcoma cell line. 11 A standard curve was generated with human TNF-a. The sensitivity of the assay was 5-25 pg/ml for serum and 75-375 pg/g wet weight for lung.
Construction of recombinant Adenovirus expressing hIL-10, vIL-10, or empty cassette A derivative of human adenovirus serotype 5 was used as the source of viral DNA backbone. This modified adenoviral vector backbone contains a deletion of bp 355-4021, resulting in a deletion of the E1a, E1b, and protein IX polypeptides. In addition, there is a deletion of bp 28, 592-630, and 470 that results in a loss of 1.9 kb of DNA from the E3 region. Recombinant adenovirus expressing hIL-10 and vIL-10 cDNA transgenes were constructed by standard homologous recombination methods as described by Graham and Prevec. 34 Briefly, hIL-10 and vIL-10 cDNAs containing the full-length translated regions (from pDSRG-IL10 and pcDSR-BCRF1 plasmids, respectively, obtained from K. Moore at DNAX Research Institute, Palo Alto, CA, USA; 35 ) were subcloned into the BamHI/XbaI cloning site of the pACN transfer plasmid. The pACN transfer plasmid is based on pBR322 and contains, from 5 0 to 3 0 , the Ad5 inverted terminal repeat and packaging signal (Ad5 bp 1-358), the hCMV immediate early enhancer/promoter, the Ad2 tripartite leader sequence, a multiple cloning site, and Ad2 bp 4021-10457. This plasmid was transfected into 293 cells, along with a ClaI-linearized fragment of the plasmid containing the modified hAd5 adenoviral vector IL-10 gene therapy in MSOF PF McAuliffe et al backbone described above. 34 Additionally, a recombinant adenovirus containing an empty expression cassette was constructed for use as a control. All of the viral constructs were similar, with the exception of the transgene, and the production and purification procedures were identical.
Statistical analysis
Data are presented as the mean7s.e.m. (n ¼ 9-24 animals/group). Student's t-test was used for analyses comparing healthy controls to vehicle-treated animals. Two-way ANOVA was used to compare animals at the same time point receiving different treatments (buffer, Ad/hIL-10, or Ad/vIL-10), and post hoc comparisons were performed with Dunn's multiple range test. Survival was assessed with Kaplan-Meier analysis. Statistical differences were considered to be significant at Po0.05.
